Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Elbit Medical Technologies Ltd's Subsidiary Receives CE Approval For ExAblate System


Monday, 3 Dec 2012 07:00pm EST 

Elbit Medical Technologies Ltd announced that its subsidiary, InSightec, has received Council of Europe (CE) mark approval for its ExAblate System. The ExAblate system is a radiation-free treatment that provides pain relief for individuals suffering from bone tumor pain. 

Company Quote

18.0
0.9 +5.26%
14 Jul 2014